Targeted therapies in breast cancer

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Metastatic breast cancer treatment has been significantly improved by targeted therapies.
• Key molecular targets include epidermal growth factor receptor (EGF R) family signaling, DNA repair pathways, and angiogenesis.

Purpose of the Study:

• To provide a concise review of recent advancements in targeted therapies for breast cancer.
• To focus on new molecular targets and their therapeutic implications.

Main Methods:

• Review of current literature on targeted breast cancer therapies.
• Focus on EGF R signaling, PARP inhibitors, and antiangiogenic agents.
• Discussion of predictive biomarkers for targeted treatments.

Main Results:

• Blocking EGF R signaling (ErbB2) with antibodies or kinase inhibitors is effective in ErbB2-positive breast cancer.
• Poly-ADP-ribose polymerase (PARP) inhibitors induce synthetic lethality in tumors with DNA double-strand repair deficiencies.
• Anti-VEGF antibodies inhibit tumor angiogenesis and extend progression-free survival.

Conclusions:

• Targeted therapies offer improved outcomes for metastatic breast cancer.
• Predictive biomarkers are crucial for optimizing PARP inhibitor and antiangiogenic therapy efficacy.
• EGF R family signaling has established predictive markers, guiding its targeted treatment.